A23L3/3553

A METHOD FOR TREATING AND CONTROLLING POST-HARVEST PHYSIOLOGICAL DISORDERS IN FRUIT VIA EDIBLE COATINGS
20200214305 · 2020-07-09 ·

The present invention describes the method for treating and controlling physiological disorders that are caused during the post-harvest process of fruit, which comprises the application of an aqueous solution which is a edible coating and said coating comprising at least one phospholipid, or at least one polysorbate, or at least a sorbitan ester, or at least a sucrose ester of fatty acids or at least a sucroglyceride of fatty acids or a combination thereof the application being during any one of the stages of the post-harvest process to their shipment and sale at their final destination.

A METHOD FOR TREATING AND CONTROLLING POST-HARVEST PHYSIOLOGICAL DISORDERS IN FRUIT VIA EDIBLE COATINGS
20200214305 · 2020-07-09 ·

The present invention describes the method for treating and controlling physiological disorders that are caused during the post-harvest process of fruit, which comprises the application of an aqueous solution which is a edible coating and said coating comprising at least one phospholipid, or at least one polysorbate, or at least a sorbitan ester, or at least a sucrose ester of fatty acids or at least a sucroglyceride of fatty acids or a combination thereof the application being during any one of the stages of the post-harvest process to their shipment and sale at their final destination.

Sterilizing Agent Becoming Edible and/or Drinkable By Heat Treatment After Used For Sterilization

Provided herein is a sterilizing agent which is edible and/or drinkable after used for sterilization, has an excellent sterilizing effect in a neutral pH range and high safety for a human body, and can be suitably used as a sterilizing agent or an additive for an object such as various liquids, solids, or foods and drinks. The sterilizing agent according to the present invention comprises a strong acidic food additive and a strong alkali salt.

Sterilizing Agent Becoming Edible and/or Drinkable By Heat Treatment After Used For Sterilization

Provided herein is a sterilizing agent which is edible and/or drinkable after used for sterilization, has an excellent sterilizing effect in a neutral pH range and high safety for a human body, and can be suitably used as a sterilizing agent or an additive for an object such as various liquids, solids, or foods and drinks. The sterilizing agent according to the present invention comprises a strong acidic food additive and a strong alkali salt.

Treatment of autism spectrum disorder and associated symptoms
10688179 · 2020-06-23 ·

Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

Treatment of autism spectrum disorder and associated symptoms
10688179 · 2020-06-23 ·

Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

COATING COMPOSITIONS INCLUDING CO-SURFACTANTS
20240090389 · 2024-03-21 ·

The present disclosure relates to compositions including monoglycerides and co-surfactants. An exemplary embodiment includes about 40 wt % to about 99 wt % of one or more monoglycerides of a C.sub.4-C.sub.28 fatty acid, about 0.1 wt % to about 20 wt % of one or more salts of a C.sub.4-C.sub.28 fatty acid, and about 0.1 wt % to about 20 wt % of one or more zwitterions.

Nanoencapsulation of Jania rubens seaweeds' antioxidants for food applications
20240090537 · 2024-03-21 ·

An additive for food products to extend shelf-life is provided where the additive is nanoparticles having extracted phytochemicals or anti-oxidants from Jania Rubens nano-encapsulated with chitosan-tripolyphosphate. Shelf-life was extended in contrast to the synthetic preservatives which are typically used in the food industry. The cost of the natural preservative is much less than that of the synthetic preservatives. Extension of shelf-life by a natural source is nowadays more desirable by the consumers due to the modem trends of consumption of food with no chemical preservatives.

Nanoencapsulation of Jania rubens seaweeds' antioxidants for food applications
20240090537 · 2024-03-21 ·

An additive for food products to extend shelf-life is provided where the additive is nanoparticles having extracted phytochemicals or anti-oxidants from Jania Rubens nano-encapsulated with chitosan-tripolyphosphate. Shelf-life was extended in contrast to the synthetic preservatives which are typically used in the food industry. The cost of the natural preservative is much less than that of the synthetic preservatives. Extension of shelf-life by a natural source is nowadays more desirable by the consumers due to the modem trends of consumption of food with no chemical preservatives.

TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS
20190351054 · 2019-11-21 ·

Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.